Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Arizona Tribune - Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

ECONOMY 27.01.2026

JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

Text size:

Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Jupiter Neurosciences at www.jupiterneurosciences.com.

Event Details:

Conference: 3rd Annual DealFlow Discovery Conference
Venue: The Borgata Hotel, Casino & Spa
Location: Atlantic City, NJ
Date: January 28-29, 2026

Investors interested in scheduling a meeting with the Jupiter Neurosciences management team should request an investor pass to attend the conference (no cost to attend).

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Media Contact:

Christer Rosén
Chairman and CEO
Jupiter Neurosciences, Inc.
[email protected]

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

K.Hill--AT

SCS	0.12%	16.14	$
RYCEF	-2.69%	16	$
RBGPF	1.65%	83.78	$
CMSC	-0.02%	23.691	$
GSK	1.86%	51.615	$
NGG	0.08%	85.12	$
CMSD	0.06%	24.075	$
BTI	0.72%	60.645	$
BP	-0.49%	37.855	$
RIO	-3.73%	91.71	$
VOD	-0.31%	14.665	$
RELX	-1.09%	35.775	$
BCE	0.88%	25.71	$
BCC	0.55%	80.61	$
AZN	0.8%	93.34	$
JRI	0.35%	13	$

Arizona Tribune - Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Featured

France rescues over 6,000 UK-bound Channel migrants in 2025

Analysts say Kevin Warsh a safe choice for US Fed chair

Fela Kuti to be first African to get Grammys Lifetime Achievement Award

Trump picks former US Fed official as next central bank chief